Company Monitoring Page for Roche

latest headlines for company on cafepharma

Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Fierce Pharma
Tue, 11/20/18 - 12:15 pm
Tags:
Roche, Merck, Pfizer, Tecentriq, kidney cancer
Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market
BioSpace
Mon, 11/19/18 - 11:25 am
Tags:
Tesaro, Roche, Gilead Sciences, M&A
Genentech to pay Immunocore $100M to co-develop preclinical MAGE-A4 drug
Fierce Biotech
Mon, 11/19/18 - 09:54 am
Tags:
Genentech, Roche, MAGE-A4, IMC-C103C, Immunocore
7 drugs that raised eyebrows in Q3
Biopharma Dive
Thu, 11/15/18 - 11:50 pm
Tags:
Sanofi, Dupixent, Roche, Herceptin, AbbVie, Humira, Regeneron, Repatha, Clovis Oncology, Rubraca, GSK, Shingrix, Eli Lilly, Trulicity
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Tue, 11/13/18 - 09:51 am
Tags:
Roche, Genentech, Tecentriq, Celgene, Abraxane, FDA, triple negative breast cancer
Genentech details claims Sanofi partner JHL used stolen trade secrets to develop rival drugs at an 'astonishing pace'
Endpoints
Fri, 11/9/18 - 12:10 pm
Tags:
Genentech, Roche, JHL Biotech, trade secrets
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Mon, 11/5/18 - 11:53 am
Tags:
Novartis, Sandoz, FDA, biosimilars, Roche, Rituxan
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Sat, 11/3/18 - 04:05 pm
Tags:
Celgene, Revlimid, Roche, Rituxan, follicular lymphoma
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Sat, 11/3/18 - 12:39 pm
Tags:
Novartis, Sandoz, rituximab, biosimilars, Roche
Roche and AbbVie Push Towards First-Line CLL Treatment
BioSpace
Thu, 11/1/18 - 11:28 am
Tags:
Roche, Genentech, AbbVie, clinical trials, Venclexta, Gazyva, CLL, chronic lymphocytic leukemia
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Mon, 10/29/18 - 10:27 am
Tags:
Roche, Genentech, Regeneron, Novartis, Eylea, faricimab, wet-AMD
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
Pharmaforum
Fri, 10/26/18 - 09:54 am
Tags:
NICE, AbbVie, Venclyxto, Roche, Rituxan/MabThera, CLL
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Thu, 10/25/18 - 11:43 am
Tags:
Regeneron, Eylea, diabetic retinopathy, Roche, Lucentis
FDA Approves First New Flu Drug in Nearly 20 Years
CP Wire
Wed, 10/24/18 - 01:21 pm
Tags:
FDA, Xofluza, Flu, Shionogi, Roche, Tamiflu
Wed, 10/24/18 - 12:39 pm
Tags:
Shionogi, Roche, Xofluza, Tamiflu, influenza
Not So Fast With Immune Therapy For Breast Cancer
Forbes
Mon, 10/22/18 - 11:14 pm
Tags:
breast cancer, immunotherapy, Roche
Loxo's targeted therapy holds up to Roche challenge
Biopharma Dive
Sun, 10/21/18 - 11:36 pm
Tags:
Roche, entrectinib, Loxo Oncology, Ignyta, Bayer, larotrectinib
Benefit of Roche's Tecentriq looks limited in breast cancer
Biopharma Dive
Sat, 10/20/18 - 11:01 pm
Tags:
Roche, Tecentriq, breast cancer, triple negative breast cancer
Roche leaves Abbott in the dust when it comes to US approval times
EP Vantage
Fri, 10/19/18 - 09:27 am
Tags:
devices, FDA, device approvals, Roche, Abbott Labs, Becton Dickinson
Roche torches a mountain of biobucks, sweeping out a roster of R&D programs in the latest pipeline cleanup
Endpoints
Wed, 10/17/18 - 09:13 am
Tags:
Roche, earnings, R&D, RG6125, Actemra, RG7155

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.